New Drug Duo Helps Cut Colon Cancer Risk

And cancer drug Sutent may slow liver cancer progression, scientists report

By Steven Reinberg
HealthDay Reporter

Related Encyclopedia • Adenocarcinoma of the Lung and Brain Metastases • Arteriohepatic Dysplasia • Basal Cell Carcinoma • Bladder Cancer More... Related Healthscout Videos Zapping Vocal Tumors Keep Away Ovarian Cancer Breakthrough for Fatal Lung Disease Preventing Breast Cancer More... Related Animations • Breast Self-Exam Video • Colon Cancer • Hepatitis More... Related Drug Information • Epogen • Iressa • Procrit • Topamax More... Related News Articles • Mood Disorders Put Breast Cancer Patients at Risk for PTSD • Training Student Leaders Cuts Peers' Smoking Rates • Outside Workers Least Likely to Get Skin Exams • Breast Cancer Tends to Grow Faster in Younger Women More...

MONDAY, April 14 (HealthDay News) -- A new drug duo might help prevent colorectal cancer, and the powerful new cancer drug Sutent may slow the progression of liver cancer.

So conclude two studies presented Monday at the American Association for Cancer Research annual meeting in San Diego.

Text Continues Below

---

In the first report, researchers found that a two-drug regimen made up of low doses of difluoromethylornithine (DFMO) plus sulindac, a non-steroidal anti-inflammatory drug (NSAID), cut the risk of colorectal adenomas by up to 95 percent. Colorectal adenomas are an early sign of colon cancer.

"We really think we are on track to develop a medical means to prevent colon cancer," lead researcher Dr. Frank L. Meyskens, a professor of medicine at the University of California, Irving, told reporters during a Monday afternoon teleconference.

Meyskens believes the drug combo could be used for people at high risk for colon cancer to prevent the disease from developing. It could also be used by those who have already had colon cancer, to help prevent its return, he said.

In the phase III trial, researchers studied 375 people with a history of colorectal polyps. They randomly assigned patients to a combination of DMFO and sulindac or placebo. Patients were followed for three years.

Patients taking the combination of drugs saw a 70 percent reduction in the risk of a new adenoma compared with patients receiving placebo.

For people who had advanced adenomas, the risk of developing new adenomas was reduced by 92 percent among those on the drug combination, Meyskens said.

Moreover, patients taking the drug combination who had had large adenomas saw a 90 percent reduction in their risk of developing new adenomas compared with patients taking placebo.

"The real home run was that we had a 95 percent decrease in new adenomas in those patients who had multiple adenomas," Meyskens said. "So, 17 patients in the placebo group had more than one adenoma, compared with only one patient in the treatment group," he said.

Page:  1 | 2 | 3 | Next >>